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Abstract
Background: PALETTE is a phase 3 trial that demonstrated single-agent activity of pazopanib in advanced soft
tissue sarcomas (aSTS). We performed retrospective subgroup analyses to explore potential relationships between
patient characteristics, prior lines of therapy, dose intensity, and dose modifications on safety and efficacy of
pazopanib in aSTS.
Methods: PALETTE compared pazopanib with placebo in patients with aSTS (age ≥ 18 years) whose disease had
progressed during or following prior chemotherapy. In these subgroup analyses, median progression-free survival
(mPFS) among patients receiving pazopanib was the efficacy outcome of interest. Adverse events (AEs) were also
compared within subgroups. All analyses were descriptive and exploratory.
Results: A total of 246 patients received pazopanib in the PALETTE study. The mPFS was longer in patients who
had only 1 prior line versus 2+ prior lines of therapy (24.7 vs 18.9 weeks, respectively); AE rates were similar
regardless of number of prior lines of therapy. The mPFS was similar in patients aged < 65 and ≥ 65 y (20.0 and
20.1 weeks, respectively). Although AEs leading to study discontinuation were higher in older patients (≥65 y, 30%;
< 65 y, 17%), rates of dose reductions, dose interruptions, and serious AEs were similar between the 2 age groups.
No reduction in mPFS was noted in patients requiring dose reductions or dose interruptions to manage toxicities.
Conclusions: Longer mPFS was observed in patients receiving pazopanib following only 1 line of therapy. Additionally,
mPFS with pazopanib was maintained regardless of patient age or dose modifications used to manage toxicity.
Trial registration: NCT00753688, first posted September 16, 2008 (registered prospectively).
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Background
Pazopanib is an oral, small-molecule tyrosine kinase
inhibitor (TKI) targeting vascular endothelial growth
factor (VEGF) receptors (VEGFR-1, − 2, and − 3), plate-
let-derived growth factor (PDGF) receptors (PDGFR-
alpha and -beta), fibroblast growth factor receptor, and
KIT [1]. The predominant role of VEGF and PDGF in
tumor angiogenesis and their expression across many
soft tissue sarcoma (STS) subtypes provided a strong ra-
tionale for the evaluation of pazopanib in STS. In a pla-
cebo-controlled, randomized, phase 3 trial in patients
with advanced STS (aSTS; excluding liposarcomas and
gastrointestinal stromal tumor [GIST]), pazopanib ad-
ministration led to significantly improved progression-
free survival (PFS) compared with placebo [2]. These
results led to the US regulatory approval of pazopanib
for treating patients with aSTS who have previously
received chemotherapy [3]. The EMA has approved
pazopanib for adults with selected subtypes of aSTS
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following prior chemotherapy for metastatic disease or
after progression within 12months after (neo)adjuvant
therapy [4]. Pazopanib was the first molecularly targeted
agent approved for treating aSTS at a time when treat-
ment options following failure of first-line chemotherapy
(the most common first-line treatment) were very limited.
The incidence of STS increases with age, with approxi-
mately 50% of newly diagnosed patients being older than
65 years [5]. In addition to the high-grade and/or high-
stage STS presentation in elderly patients versus younger
patients [6, 7], poor prognosis in older patients might
also relate to undertreatment based on misconceptions
of tolerability and safety [8]. Older patients are less likely
to be treated with adjuvant chemotherapy, radiotherapy,
or definitive surgery [9]. Also, comorbidities are gener-
ally more common in older rather than younger patients.
Underrepresentation of elderly patients further compro-
mises the generalizability of the clinical trial findings to
clinical practice [10]. Number of prior lines of therapy
also influences STS outcomes. In a retrospective study
evaluating novel targeted therapies in patients with aSTS
after progression from US FDA-approved therapies,
patients who had received 2 or fewer prior lines of treat-
ment had substantially improved overall survival (OS) in
comparison with patients who had received 3 or more
prior lines of treatment [11].
Flexibility of pazopanib dosing in patients with aSTS
may be crucial for optimal treatment and tolerability in
this setting. In the PALETTE trial, dose interruptions and
dose reductions were allowed to manage adverse events
(AEs). Pazopanib treatment was temporarily interrupted
in 49% of patients, and 39% of patients received dose re-
ductions. A definitive treatment discontinuation due to
AEs related to pazopanib occurred in 14% of patients [2].
However, limited data have been published to date on
pazopanib efficacy and safety in patients undergoing dose
interruptions and dose reductions.
Using data from the PALETTE trial, we investigated
pazopanib efficacy and safety in specific subgroups of
patients with aSTS. Understanding the influence of age,
prior lines of therapy, dosing intensity, and dose modifi-
cations on pazopanib outcomes could potentially allevi-
ate safety and tolerability concerns and guide optimal
usage of pazopanib in patients with aSTS.
Methods
Study design
PALETTE (EORTC 62072) was a randomized, double-
blind, placebo-controlled, phase 3 trial, conducted by the
Soft Tissue and Bone Sarcoma Group of the European
Organization for Research and Treatment of Cancer be-
tween October 2008 and November 2010. Patients were
randomized 2:1 to receive either pazopanib 800 mg once
daily or placebo, with no subsequent cross-over. As part
of the original study [2], all patients provided written in-
formed consent and the trial was approved by all rele-
vant review bodies. Because the subgroup analyses used
existing data from the primary study, additional consent
was not required. The study was conducted in accord-
ance with the Declaration of Helsinki and Good Clinical
Practice guidelines. Full details of the PALETTE study
design, including inclusion and exclusion criteria, have
been published previously [2].
Subgroups of interest in our current post hoc analyses
were based on the following metrics: prior lines of ther-
apy (only 1 prior line of therapy vs 2+ prior lines of
therapy), age (< 65 years vs ≥65 years) dose intensity
(dose < 400 mg, ≥400 mg to < 600mg, and ≥ 600 mg to
≤800 mg), and dose modifications (no dose reduction vs
dose reductions; no dose interruption vs dose interrup-
tions) among patients randomized to receive pazopanib
in the PALETTE trial. All subgroup analyses were
exploratory and descriptive in nature, with no statistical
hypothesis testing.
Eligibility criteria
Key inclusion criteria included patients of age ≥ 18 years
with aSTS and disease progression within 6 months prior
to receiving study drug or within 12 months of previous
adjuvant treatment, ≥1 regimen containing anthracy-
cline, and ≤ 4 lines of prior systemic therapy for meta-
static disease. No more than 2 previous lines should have
been combination regimens, and (neo)adjuvant/mainten-
ance treatments were not counted toward this criterion.
Key exclusion criteria included patients with adipocytic
sarcoma, embryonal rhabdomyosarcoma, chondrosar-
coma, osteosarcoma, and GIST. Patients with clinically
abnormal cardiac function or poorly controlled hyperten-
sion were also excluded. Patients who had had a cerebro-
vascular accident, pulmonary embolism, untreated deep
venous thrombosis, or clinically significant gastrointestinal
disorders in the past 6months were ineligible.
Criteria for dose modifications
Dose interruptions or reductions were permitted follow-
ing potential drug-related toxicities including but not
limited to hypertension, proteinuria, hepatotoxicity,
bleeding events, thrombosis, and thrombocytopenia/
neutropenia. In cases wherein a dose reduction was
necessary, 2 stepwise dose reductions were permitted:
initially to 600 mg and subsequently to 400mg. If the
toxicity did not recur or worsen, the doses could be
increased stepwise back to 600 mg and 800 mg after
monitoring for 10–14 days at each step. If a patient’s
treatment had been interrupted > 14 days due to toxicity,
resumption of treatment was based on patient’s condi-
tion and recovery from toxicity at reduced dose. An
additional table provides a detailed description of
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protocol-defined and prespecified dose modifications for
potential treatment-related AEs (see Additional file 1).
Study endpoints
The primary objective of the PALETTE trial was to dem-
onstrate superiority in PFS of pazopanib over placebo. In
this subgroup analysis, the efficacy outcome of interest
was median PFS (mPFS) among pazopanib recipients in
the PALETTE trial. Adverse events were also compared
within the subgroups.
Statistical analysis
Efficacy was evaluated in the intent-to-treat population,
which included all patients who were randomized to treat-
ment. Although the PALETTE study was stratified accord-
ing to number of previous lines of systemic therapy and
was powered to detect a 15% difference in PFS (pazopanib
versus placebo arms) at 6months, the study was not pow-
ered for any subgroup analyses. The safety population,
which was defined as all patients who were administered
their allocated treatment and had received at least 1 dose
of the study drug, was used for all safety analyses.
Results
Patient characteristics
A total of 246 patients were randomized to the pazopa-
nib arm and represented the intention-to-treat (ITT)
population. At baseline, the mean age was 54 (±15)
years, 60% of patients were female, and 25% of the pa-
tients were ≥ 65 years of age (Table 1). At the time of the
primary analysis, median follow-up was 14.9 months
(interquartile range, 11.0–18.2) in the pazopanib group;
disease progression was documented in 168 recipients
and 137 patients had died.
Subgroup analysis by age
Among patients receiving pazopanib, 184 patients
were < 65 years of age and 62 patients were ≥ 65 years
of age. The mPFS was similar in the 2 age subgroups
(age < 65 years, 20.0 [95% CI, 17.9–22.0] weeks and
age ≥ 65 years, 20.1 [95% CI, 11.7–31.6] weeks, re-
spectively). Treatment-related AEs occurred in 93% of
patients < 65 years of age versus 85% of patients ≥65
years of age (Table 2). The AEs leading to study dis-
continuation occurred at a higher rate in older (≥65
years) versus younger (< 65 years) patients (30% vs
17%, respectively). However, rates of dose reductions,
dose interruptions, and serious AEs leading to study
discontinuation were similar between the 2 age
groups (Table 2).
Subgroup analysis by prior lines of therapy
Among patients receiving pazopanib, 110 patients had
received 1 prior line of therapy and 136 patients had
received 2 or more prior lines of therapy. The mPFS was
higher in patients with 1 prior line of therapy (24.7
weeks [95% CI, 19.6–27.4]) versus patients with 2 or
more prior lines of therapy (18.9 weeks [95% CI, 11.9–
20.1]). Rates of AEs were similar between the 2 sub-
groups (Table 3).
Subgroup analysis by dose intensity
Among patients receiving pazopanib, the majority (n = 234)
received doses between 600 and 800mg daily. Only 4 pa-
tients received doses between 400 and 600mg daily, and 7
patients received doses less than 400mg daily. Among pa-
tients receiving the highest doses, mPFS was 20.1 weeks
(95% CI, 17.9–21.3). Patients who received between 400
and 600mg pazopanib daily had mPFS of 25.3 weeks (95%
CI, 8.1–38.1), and mPFS was 5.1 weeks (95% CI, 3.3–7.0) in
patients who received less than 400mg pazopanib daily.
Subgroup analysis by dose modifications
Among patients receiving pazopanib, patients with 1 or
more dose reductions had substantially higher mPFS
than patients with no dose reductions (27.7 weeks [95%
CI, 21.1–35.7] vs 11.9 weeks [95% CI, 8.9–19.3], respect-
ively) (Table 4). Similarly, patients with 1 or more dose
interruptions had substantially higher mPFS than pa-
tients with no dose interruptions (21.3 weeks [95% CI,
20.1–27.7] vs 11.0 weeks [95% CI, 8.1–19.3], respect-
ively) (Table 4).
Discussion
In this PALETTE subgroup analysis, the magnitude of
clinical benefit observed with pazopanib was similar
Table 1 Baseline Characteristics of Pazopanib Recipients in the
PALETTE Trial (ITT Population)
Pazopanib Arm
(n = 246)
Age, y, mean (SD) 54.0 (14.9)
< 65 y, n (%) 184 (75)
≥65 y, n (%) 62 (25)
Female, n (%) 147 (60)
Weight, kg, mean (SD) 71.5 (16.9)
STS subtypes, n (%)
Leiomyosarcoma 109 (44)
Synovial sarcoma 25 (10)
Other STS histologies 112 (46)
Time since initial diagnosis, mo, median (IQR) 26.6 (14.5–46.1)
Time since last progression, mo, median (IQR) 0.7 (0.3–1.1)
Prior lines of therapy, n (%)
1 110 (45)
2 or more 136 (55)
SD standard deviation, STS soft tissue sarcoma, IQR interquartile range
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between elderly and younger patients. Increasing age
was apparently unrelated to mPFS. Higher rates of AEs
leading to study discontinuation in older patients are
not surprising, likely due to a higher prevalence of co-
morbidities and reduced tolerability in elderly com-
pared with younger patients. However, rates of dose
reductions, dose interruptions, and serious AEs were
similar between the two age groups. Retrospective ana-
lyses of patients receiving other therapies for aSTS have
reported similar findings of a higher rate of AEs in eld-
erly patients compared with their younger counterparts
[12, 13]. Because the AE profile of each agent may vary,
the individual safety profile of each agent should inform
treatment decisions in the elderly, especially in the
presence of comorbidities.
As might be expected, the number of lines of previous
systemic therapy was a significant prognostic factor for
PFS among pazopanib recipients in the PALETTE study
(0–1 vs 2–4 prior lines of therapy, HR [95% CI]: 0.72
[0.53–0.99]; P = 0.04) [2]. This finding is in agreement
with “real-world evidence” demonstrating that patients
with aSTS exhibit a decline in mPFS with each add-
itional line of previous therapy [14]. The randomized,
phase 2 EPAZ trial (NCT01861951) demonstrated that
pazopanib was noninferior to doxorubicin with respect
to PFS in the first-line treatment of STS in patients more
than 60 years of age [15]. Recent studies have suggested
that in some cases systemic anticancer therapy may pro-
mote progression of cancer rather than only influencing
cancer evolution [16–18]. STS are characterized by
tumor heterogeneity, and evolution of tumor heterogen-
eity in response to therapy is a well-established
phenomenon [19]. Mutagenesis driven by cytotoxic ther-
apies or by acquired chromosomal instability could drive
clonal selection, leading to greater intratumoral hetero-
geneity and thereby increasing the likelihood of resist-
ance to subsequent treatment [19]. Treatment sequence
had no effect on pazopanib’s safety profile, as evidenced
by similar AE rates between the 2 subgroups based on
prior lines of therapy.
In a subgroup analysis by pazopanib dose, patients re-
ceiving a daily dose between 400 and 600 mg had higher
mPFS than patients receiving a daily dose between 600
and 800 mg or a daily dose of less than 400 mg; however,
due to the small numbers of patients in the lower-dose
subgroups, these results should be interpreted cau-
tiously. Patients with metastatic renal cell carcinoma
(RCC) receiving a lower starting dose of first-line
Table 2 Adverse Events in Pazopanib Recipients by Age Subgroups (Safety Population)




Any on-therapy AE 178 (99) 59 (98)
AEs related to study treatment 168 (93) 51 (85)
AEs leading to permanent discontinuation or early withdrawal 30 (17) 18 (30)
AEs leading to dose reduction 60 (33) 17 (28)
AEs leading to dose interruption/delay 89 (49) 31 (52)
Any SAE 75 (42) 24 (40)
SAEs related to study treatment 40 (22) 17 (28)
Fatal SAEs 7 (4) 1 (2)
Fatal SAEs related to study treatment 1 (< 1) 0 (0)
AE adverse event, SAE serious adverse event.
Table 3 Adverse Events in Pazopanib Recipients by Number of Prior Lines of Therapy (Safety Population)




Any on-therapy AE 108 (> 99) 129 (98)
AEs related to study treatment 101 (93) 118 (90)
AEs leading to permanent discontinuation or early withdrawal 24 (22) 24 (18)
AEs leading to dose reduction 38 (35) 39 (30)
AEs leading to dose interruption/delay 59 (54) 61 (47)
Any SAE 47 (43) 52 (40)
SAEs related to study treatment 26 (24) 31 (24)
Fatal SAEs 5 (5) 3 (2)
Fatal SAEs related to study treatment 0 (0) 1 (< 1)
AE adverse event, SAE serious adverse event.
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pazopanib fare worse compared with those receiving a
standard dose [20]. At a median follow-up of 13.9
months, patients receiving reduced starting dose (400 or
600 mg/day) versus standard dose (800 mg/day) have
shown substantially reduced objective response rates
(19% vs 44%, respectively) and increased discontinuation
rates due to progressive disease (44% vs 28%,
respectively) [20].
Intriguingly, patients receiving pazopanib with 1 or
more dose reductions or dose interruptions because of
drug toxicity had improved mPFS compared with pa-
tients in whom dose modifications were not required.
These findings are consistent with those of the COM-
PARZ study in advanced renal cell carcinoma, wherein
longer mPFS in pazopanib-treated patients was observed
when dose modification was required because of toxicity,
suggesting that patients are not at a disadvantage when
such dose reductions or interruptions are needed [21].
In this context, “on-target” toxicities of TKIs have been
suggested as potential indicators of efficacy [22]. In a
pharmacokinetics/pharmacodynamics study in patients
with RCC, the threshold concentration for pazopanib
efficacy overlapped with concentrations at which toxicity
occurs [23]. Evidence from previous reports and this
study suggests that pazopanib recipients with no toxicity
signs and symptoms (and thus not requiring a dose
modification) may have suboptimal therapeutic drug
exposure. However, the post hoc observational analysis
in the current study did not account for the timing of
dose modifications on treatment efficacy. A potential for
bias due to early discontinuation in the groups with no
dose reductions or interruptions subgroups cannot be
ruled out, and hence, the effects of dose reductions and
dose interruptions on mPFS outcomes need cautious
interpretation.
This study has some additional limitations. Only data
from subgroups of patients that received pazopanib were
evaluated. All analyses were post hoc, descriptive, and
exploratory in nature, and were not designed to permit
statistical comparison across subgroups. For this reason,
the possibility of bias in the descriptions of treatment
effects in the post-randomization subgroups cannot be
ruled out. Our findings therefore should be considered
preliminary and will need to be confirmed in “real-
world” settings.
Conclusions
In conclusion, longer mPFS was observed in patients
receiving pazopanib as a second-line therapy for aSTS, ra-
ther than in later lines of treatment. Also, mPFS with
pazopanib was maintained irrespective of patient age or
the use of dose modifications for management of toxicity.
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